Glioblastoma is a aggressive brain tumor known for its quick growth and resistance to conventional treatments. Studies are constantly underway to identify new management strategies, and recently, a novel biomarker named LCA168 has emerged as a potential focus for GBM treatment. LCA168 is a protein that is overexpressed in glioblastoma cells compar